219 research outputs found
918-7 Limitations of Percutaneous Interventions in the Treatment of Bifurcation Lesions Involving the Left Anterior Descending Coronary Artery
Serious complications may occur when intervention is unsuccessful in bifurcation lesions involving the left anterior descending (LAD) and first major diagonal (D), because of the large amount of involved myocardium. To determine this complication rate, we reviewed 82 consecutive cases, over a 3 year period, in which these lesions were attempted. Sixty-six percent of the subjects were male, and 37% had unstable angina. The mean age was 59 and the mean ejection fraction was 56%. Digital calipers were used to measure vessel minimum lumen (MLD) and reference diameters. For the LAD the final MLD was 1.81mm and for the 0 1.32mm. The final percent mean diameter stenoses for the LAD and D were 41% and 45%, respectively. There were no significant differences in the rates of success or complication between groups treated with angioplasty only (N=68) or directional atherectomy (N=14). The in-hospital event-free success rate was 55%. The in-hospital complication rates were:Recurrent Ischemia16%Ventricular Tachycardia2%Myocardial Infarction14%Stroke2%Bypass Surgery12%Death1%Repeat Procedure4%Composite34%ConclusionLAD bifurcation lesion intervention is associated with a high in-hospital complication rate. Since these lesions are not amenable to stent placement or atherectomy with simultaneous protection of both vessels, these cases should be carefully evaluated before intervention, and bypass surgery should be considered as a treatment option
Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers,
including head and neck cancer. However, there is limited information on its role in oropharyngeal
squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present metaanalysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated
in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was
evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients,
were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined
hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence
interval (CI) 1.21–2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34–1.73; p < 0.00001),
and for recurrence-free survival was 1.86 (95% CI 1.50–2.30; p < 0.00001). This worse prognosis ofhigh NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05
(95% CI 1.90–8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47–1.80; p = 0.82).
The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with
radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09–2.01; p = 0.01), and for patients
treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08–2.72; p = 0.02). In conclusion, an elevated
NLR relates to worse outcomes in patients with HPV-positive OPSCC.info:eu-repo/semantics/publishedVersio
In-beam internal conversion electron spectroscopy with the SPICE detector
The SPectrometer for Internal Conversion Electrons (SPICE) has been
commissioned for use in conjunction with the TIGRESS -ray spectrometer
at TRIUMF's ISAC-II facility. SPICE features a permanent rare-earth magnetic
lens to collect and direct internal conversion electrons emitted from nuclear
reactions to a thick, highly segmented, lithium-drifted silicon detector. This
arrangement, combined with TIGRESS, enables in-beam -ray and internal
conversion electron spectroscopy to be performed with stable and radioactive
ion beams. Technical aspects of the device, capabilities, and initial
performance are presented
Half-lives of neutron-rich Cd 128-130
R. Dunlop et al. ; 6 págs.; 7 figs.; 1 tab. ; Rapid CommunicationsThe β-decay half-lives of Cd128-130 have been measured with the newly commissioned GRIFFIN γ-ray spectrometer at the TRIUMF-ISAC facility. The time structures of the most intense γ rays emitted following the β decay were used to determine the half-lives of Cd128 and Cd130 to be T1/2=246.2(21) ms and T1/2=126(4) ms, respectively. The half-lives of the 3/2+ and 11/2- states of Cd129 were measured to be T1/2(3/2+)=157(8) ms and T1/2(11/2-)=147(3) ms. The half-lives of the Cd isotopes around the N=82 shell closure are an important ingredient in astrophysical simulations to derive the magnitude of the second r-process abundance peak in the A∼130 region. Our new results are compared with recent literature values and theoretical calculations. ©2016 American Physical SocietyThis work has been partially supported by the Natural Sciences
and Engineering Research Council of Canada (NSERC)
and the Canada Research Chairs Program. I.D. and R.C.-F. are
supported by NSERC Discovery Grants SAPIN-2014-00028
and RGPAS 462257-2014. A.J. acknowledges financial support
by the Spanish Ministerio de Ciencia e Innovación under
contract FPA2011-29854-C04 and the Spanish Ministerio
de EconomÃa y Competitividad under contract FPA2014-
57196-C5-4-P. S.L.T acknowledges financial support from
the U.S. National Science Foundation under contract NSF-
14-01574. E.P.-R. acknowledges financial support from the
DGAPA-UNAM under the PASPA program. The GRIFFIN
spectrometer was funded by the Canada Foundation for
Innovation, TRIUMF, and the University of Guelph. TRIUMF
receives federal funding via a contribution agreement with the
National Research Council of Canada.Peer Reviewe
Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck : Opportunities in the Immunotherapy Era
Simple Summary Therapies for squamous cell carcinomas of the head and neck (SCCHN) have been rapidly evolving, initially with the inclusion of immunotherapy, but more recently with the consideration of anti-angiogenic therapies. Recent preclinical and clinical data reveal a strong correlation between vascular endothelial growth factor (VEGF) and the progression of SCCHN, with nearly 90% of these malignancies expressing VEGF. Our review article not only elaborates on the utility of anti-VEGF therapies on SCCHN but also its interaction with the immune environment. Furthermore, we detailed the current data on immunotherapies targeting SCCHN and how this could be coupled with anti-angiogenics therapies. Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.Peer reviewe
Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck : Opportunities in the Immunotherapy Era
Simple Summary Therapies for squamous cell carcinomas of the head and neck (SCCHN) have been rapidly evolving, initially with the inclusion of immunotherapy, but more recently with the consideration of anti-angiogenic therapies. Recent preclinical and clinical data reveal a strong correlation between vascular endothelial growth factor (VEGF) and the progression of SCCHN, with nearly 90% of these malignancies expressing VEGF. Our review article not only elaborates on the utility of anti-VEGF therapies on SCCHN but also its interaction with the immune environment. Furthermore, we detailed the current data on immunotherapies targeting SCCHN and how this could be coupled with anti-angiogenics therapies. Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.Peer reviewe
Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present meta-analysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21–2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34–1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50–2.30; p < 0.00001). This worse prognosis of high NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90–8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47–1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09–2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08–2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efficacy and toxicity of a gemcitabine and cisplatin combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma. Method: Gemcitabine 1250 mg m−2 was administered on day 1 and day 8 and cisplatin 80 mg m−2 was administered on day 1 in a 3-week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were observed (ORR 16%, 95% CI 1–31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred. Time to progression was 6 months (5–7 months) with a median survival from registration of 9.6 months (95% CI 8–12 months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule
- …